ABSTRACT Background: Increased serum concentrations of plant sterols, including stigmasterol, during parenteral nutrition (PN) have been linked with serum biochemical signs of intestinal failure-associated liver disease (IFALD), whereas clinical data on their correlation to histologic liver injury have been limited. Objective: We studied interrelations between serum noncholesterol sterols and histologic liver injury in pediatric-onset intestinal failure (IF). Design: Serum plant sterols (stigmasterol, avenasterol, sitosterol, and campesterol), cholestanol, and cholesterol precursors (cholestenol, lathosterol, and desmosterol) were measured in 50 IF patients at a median age 7.3 y and in 86 matched controls. Forty patients underwent liver biopsies. Sixteen patients had been receiving PN for 45 mo, and 34 patients had received PN for 9.1 mo but had not received PN for 5.4 y. Results: Serum plant sterols were higher in patients who were currently receiving PN than in controls and were related to conjugated bilirubin (r = 0.799-0.541, P , 0.05). During PN, the ratio of serum stigmasterol to cholesterol was 3.3-fold higher in patients with portal inflammation, and the ratio of avenasterol to cholesterol was 3.9-fold higher in patients with cholestasis (P , 0.05 for both). Ratios of stigmasterol and avenasterol to cholesterol were correlated with portal inflammation (r = 0.549-0.510, P , 0.05), cholestasis (r = 0.501-0.491, P = 0.048-0.053), and serum bile acids (r = 0.591-0.608, P , 0.05). The median (IQR) ratio of serum cholestanol to cholesterol was higher during (269 1003 mg/mg cholesterol; 203-402 1003 mg/mg cholesterol) than after (175 1003 mg/mg cholesterol; 156-206 1003 mg/mg cholesterol; P , 0.001) weaning off PN and was correlated with cholestasis (r = 0.428), portal inflammation (r = 0.511), and fibrosis (r = 0.323, P , 0.05 for all). After weaning off PN, ratios of cholestenol and lathosterol to cholesterol were .2-fold higher in patients with persistent liver steatosis than in those without steatosis or controls (P , 0.01 for all), whereas lathosterol was correlated with the steatosis grade (r = 0.320, P , 0.050). Conclusions: Increased serum stigmasterol and avenasterol concentrations parallel the portal inflammation and cholestasis during PN, thereby reinforcing their contribution to IFALD. A bile acid malabsorption-driven increase in cholesterol synthesis underpins persistent liver steatosis after weaning off PN. Serum cholestanol reflects liver injury in IF patients.
INTRODUCTION
Intestinal failure (IF) 5 is characterized by extensive malabsorption that requires long-term parenteral nutrition (PN) for survival (1) . A combination of compromised intestinal function and PN often gives rise to intestinal failure-associated liver disease (IFALD), which is a major cause of morbidity and mortality in IF patients, especially in young children (2) (3) (4) . Although the cause of IFALD is known to be multifactorial, including the duration and composition of PN, its exact pathophysiologic mechanisms remain unclear (4) (5) (6) .
Histologically, IFALD is characterized by cholestasis, portal inflammation, steatosis, and fibrosis during PN, whereas fibrosis and steatosis persist after weaning off PN for largely unknown reasons (4) . Previous studies have linked increased serum concentrations of plant sterols, including stigmasterol, during PN with serum biochemical signs of IFALD both in adults and children (7) (8) (9) (10) , whereas clinical data on their correlation to histologic liver injury have been very limited (11) . Of plant sterols, stigmasterol has been shown to antagonize nuclear farnesoid receptor X (FXR)-mediated bile acid homeostasis in hepatocytes in vitro (12, 13) . Recent studies in mice have further shown that the infusion of PN emulsion-containing plant sterols or stigmasterol alone produces cholestasis, inflammation, and liver injury through the stigmasterol-mediated inhibition of canalicular bile acid (ABCB11), bilirubin (MRP2), and sterol (ABCG/5 and ABCG/8) transporter expression by antagonizing nuclear receptors FXR and liver receptor X (LXR) (14) .
Histologic liver fibrosis and steatosis are tightly correlated with the remaining small intestinal length in IF patients (4, 15) who also show marked bile acid malabsorption and an accompanying increase in bile acid and cholesterol synthesis (16) (17) (18) .
Nuclear LXR and FXR receptors regulate not only sterol and bile acid homeostasis but also lipid and glucose metabolism in hepatocytes, and experimental interference of their downstream signaling may lead to fatty and fibrotic changes of the liver (19) (20) (21) (22) (23) . Thus, intestinal resection-induced alterations in cholesterol and bile acid homeostasis may contribute to the development and maintenance of histologic liver injury in IF patients. Cholestanol, which is a cholesterol metabolite, is a sensitive indicator of cholestasis in biliary cirrhosis and biliary atresia and reflects increased serum bilirubin concentrations, but little is known about its relation to liver histology in IF (11, (24) (25) (26) (27) .
To this end, we performed a prospective, population-based, cross-sectional study on serum noncholesterol sterols in relation to liver function and histology in IF patients during and after weaning off PN. Our specific aims were to assess whether serum plant sterols (stigmasterol, avenasterol, sitosterol, and campesterol) associate with portal inflammation and cholestasis during PN and whether increased cholesterol synthesis as assessed by serum cholesterol precursors (cholestenol, lathosterol, and desmosterol) relate to persistent liver steatosis and fibrosis after weaning off PN. Furthermore, we evaluated how cholestanol, which is a sensitive indicator of cholestasis, relates to liver injury in children with pediatric onset IF.
SUBJECTS AND METHODS

Ethics
This study received ethical approval from the Helsinki University Central Hospital Ethics Committee.
Patients and study design
Medical records of patients with pediatric onset IF treated by our IF rehabilitation program from January 1984 to March 2012 were reviewed, including 35 patients who participated in our previously published study (15) . Altogether, 70 patients were identified of whom 65 patients (93%) were alive. For this study, IF was defined as .50% resection of small bowel or a duration of PN .30 d (28, 29) . We have previously shown serum plant sterol concentrations remain elevated for $1 mo after weaning off PN (10) . Therefore, patients who had been weaned off PN ,3 mo before (n = 5) the study were excluded to avoid erroneously high serum concentrations of plant sterols when we assessed patients stabilized on total enteral nutrition. Eligible patients were invited to participate in this cross-sectional study, which included a clinical examination, laboratory tests, and a liver biopsy. The serum sampling and liver biopsy were performed during the same hospital visit. An informed written consent was received from all patients or their parents. Principles of IF management in our institution have been published previously (30, 31) .
Controls
After an informed written consent, blood samples of 86 healthy day-surgery patients without evidence of hepatobiliary or gastrointestinal disease, diabetes, or dyslipidemia were used as controls for serum cholesterol and noncholesterol sterols. Age (9.1 y; range: 4.0-16 y; P = 0.437) and sex (boys:girls, 49:37; P = 0.593) distributions were not significantly different between patients and controls.
Clinical and laboratory data
Patient records were reviewed for clinical data, including gestation age and weight, duration of PN, composition of PN 3 mo before the liver biopsy, and laboratory measurements, surgical procedures, and anatomy of the remaining bowel, namely lengths of the small bowel, ileum, and colon and presence of the ileocaecal valve. The age-adjusted small-bowel length was calculated on the basis of published age-specific normal values (32) . Height and weight were expressed as z scores. BMI (in kg/m 2 ; weight divided by the square of height) was calculated for adults and Finnish-reference value-based BMI-for-age was calculated for children .2 y of age (33) .
Blood samples were taken after an overnight fast and analyzed for platelets, alanine aminotransferase, aspartate aminotransferase, glutamyl transferase (GT), bile acids, albumin, prealbumin, bilirubin, conjugated bilirubin, and coagulation markers [ie, tromboplastin time (TT), international normalized ration, and activated partial TT] by using routine hospital laboratory methods. The aspartate aminotransferase-to-platelet ratio index was calculated (34) . Plasma citrulline was measured by using an automatic amino acid analyzer (Biochrom 30 Physiologic and Midas Autosampler; Biochrom Ltd) as described previously (15) . Serum cholesterol and noncholesterol sterols, including plant sterols (ie, stigmasterol, avenasterol, sitosterol, and campesterol), cholestanol, cholesterol precursor sterols (ie, cholestenol, lathosterol, and desmosterol), and squalene were measured from nonsaponifiable material by using gas-liquid chromatography on a 50-m-long SE-30 nonpolar capillary column (Ultra 1 Column; Agilent Technologies) with 5a-cholestane as an internal standard (35) . Serum noncholesterol sterols and squalene are expressed both as concentrations (ie, mmol/L) and ratios to the cholesterol concentration of the same gas-liquid chromatography run (ie, 1003 mg/mg cholesterol) to exclude effects of varying serum lipoprotein concentrations. Parenteral plant sterol intake was estimated on the basis of an analysis of plant sterol and cholesterol contents of parenteral lipid emulsions as already described and published previously (11) .
Liver biopsies and histologic analyses
Ultrasound-guided percutaneous core needle liver biopsies were performed under general anesthesia by an experienced pediatric radiologist. After the liver biopsy, patients were followed over night at the hospital. One complication occurred; a small right-sided pneumothorax resolved spontaneously. Liver biopsies were fixed in formalin, embedded in paraffin, sliced, and stained, including by hematoxylin and eosin, Periodic-acidSchiff, reticulin, cytoceration-7, copper, and iron. Slides were analyzed together by the primary researcher and 2 pediatric pathologists who were blinded to clinical data until a consensus was reached. Lobular fibrosis (0 denoted absent, 1 denoted present, and 2 denoted prominent), portal fibrosis (0 denoted absent, 1 denoted fibrous expansions of most portal areas, 2 denoted focal portal-to-portal bridging, 3 denoted marked bridging, and 4 denoted cirrhosis), and overall fibrosis (Metavir fibrosis stage) were assessed (36) . Steatosis was evaluated as the proportion of hepatocytes affected (0 denoted absent, 1 denoted #25%, 2 denoted 25-50%, and 3 denoted .50% of hepatocytes). Intracellular cholestasis, canalicular cholestasis, and ductular cholestasis were scored as 0 (absent), 1 (minimal), 2 (marked), and 3 (prominent), and for analytic purposes, cholestasis was defined as the highest of the 3 cholestasis grades. The portal inflammatory infiltrate was graded from absent to extensive (grades 0-4), and the distribution of inflammatory cells was recorded. A detailed description of the liver biopsyassessment protocol of our research group has been published previously (4) .
Statistical analysis
Data were analyzed with IBM SPSS Statistics software (version 19.0; IBM). Descriptive statistics are presented as medians (IQRs) unless otherwise stated. Distributions were assessed by using graphs and the Kolmogorov-Smirnov test. The Kruskal-Wallis, MannWhitney U, and Fisher's exact tests were used to compare differences between groups. Correlations were tested by using Spearman's rank correlation test. To identify predictors of cholestasis and portal inflammation, single and multivariate linear regression models were performed. Statistical significance was set at 0.05. 
RESULTS
Patient characteristics
Of the eligible 60 patients, 50 patients (83%) were enrolled at a median age of 7.3 y ( Table 1) . Of these subjects, 40 patients underwent a liver biopsy. IF was caused by short-bowel syndrome in 30 patients (necrotizing enterocolitis: n = 13; midgut volvulus: n = 9; small-bowel atresia: n = 8) and by dysmotility disorders in 20 patients (Hirschsprung disease: n = 13; chronic intestinal pseudoobstruction: n = 7). Five nonparticipants had died because of septic complications (n = 2) and liver failure (n = 3).
Sixteen patients were receiving PN after 45 PN mo (13-140 mo). Thirty-four patients had weaned off PN 5.4 y before after 9.1 mo of receiving PN ( Table 1 ) (Omegaven; Fresenius Kabi) in 4 patients. Demographic variables and disease characteristics were not significantly different between patients who received olive oil alone or in combination with fish oil (data not shown). Serum citrulline, which is a marker of enterocyte mass, was higher in weaned patients than those receiving PN (Table 1) .
Liver function and histology
As shown in Table 1 , w38-56% of patients who received PN showed increased plasma concentrations of transaminases, GT, and bilirubin and decreased prealbumin, whereas most patients who had weaned off PN had a normal liver biochemistry. Altogether, 32 patients (80%) displayed some abnormalities in liver histology, including 14 patients receiving PN (88%) and 18 patients after weaning off PN (75%) (P = 0.439). Cholestasis (31% compared with 4%, respectively; P = 0.029) and portal inflammation (38% compared with 8%, respectively; P = 0.042) were more frequent in patients receiving PN than in those after weaning off PN, whereas fibrosis (88% compared with 63%, respectively) and steatosis (56% compared with 42%, respectively) were equally common during and after weaning off PN ( Table 2) .
Serum noncholesterol sterols in relation to liver function
Serum plant sterols
During PN, both serum plant sterol concentrations and their ratios to cholesterol, excluding those of campesterol, were markedly higher than those of patients who had weaned off PN or controls ( Table 3) . Serum ratios to cholesterol of all plant sterols were correlated positively with the number of weekly PN infusions (r = 0.637-0.739, P = 0.008-0.001) and amount (kcal $ kg 21 $ d
21
) of daily parenteral energy (r = 0.617-0.706, P = 0.011-0.002). Ratios of serum stigmasterol (r = 0.514, P = 0.046), avenasterol (r = 0.604, P = 0.022), and sitosterol (r = 0.587, P = 0.027) to cholesterol were correlated positively with their parenteral dosage. Ratios of serum stigmasterol (r = 0.754, P = 0.001; Figure 1 ), avenasterol (r = 0.799, P , 0.001; Figure 1 ), sitosterol (r = 0.703, P = 0.002), and campesterol (r = 0.565, P = 0.023) to cholesterol reflected serum conjugated bilirubin concentrations. Ratios of serum stigmasterol and avenasterol to cholesterol were correlated with serum bile acids (r = 0.608, P = 0.016; r = 0.591, P = 0.020, respectively) and total bilirubin (r = 0.541, P = 0.031; r = 0.565, P = 0.022, respectively). Ratios of serum stigmasterol (r = 20.558, P = 0.025) and avenasterol (r = 20.533, P = 0.033) to cholesterol were inversely associated with TT. As expected, after weaning off PN, serum plant sterol concentrations declined below control values (Table 3 ). 
Cholestanol
During PN, median ratios of serum cholestanol to cholesterol were significantly elevated compared with those in patients who had weaned off PN or controls, respectively (Table 3) . Serum cholestanol concentrations were correlated with the number of weekly PN infusions (r = 0.630, P = 0.009). When all patients were included, ratios of serum cholestanol to cholesterol were positively related to serum conjugated bilirubin (r = 0.301, P = 0.034), GT (r = 0.514, P , 0.001), aminotransferase (r = 0.500, P , 0.001), aspartate aminotransferase (r = 0.377, P = 0.007), and the aspartate aminotransferase-to-platelet ratio index (r = 0.313, P = 0.029) and inversely to TT (r = 20.427, P = 0.002), prealbumin (r = 20.294, P = 0.038), and albumin (r = 20.301, P = 0.040).
Serum cholesterol precursors
Of serum cholesterol precursors, cholestenol and lathosterol concentrations and ratios to cholesterol were significantly and equally higher during and after weaning off PN compared with controls (Table 3) . During PN, plasma GT (r = 20.508, P = 0.045) and conjugated bilirubin (r = 20.567, P = 0.022) were inversely related to the ratio of serum lathosterol to cholesterol, whereas plasma prealbumin was correlated positively with ratios of serum cholestenol (r = 0.516, P = 0.041) and lathosterol (r = 0.704, P = 0.002) to cholesterol. In short-bowel patients, ratios of serum cholestenol (r = 20.423, P = 0.020) and lathosterol (r = 20.381, P = 0.038) to cholesterol were inversely related to the absolute remaining small-bowel length.
Liver histology in relation to serum noncholesterol sterols
Portal inflammation
During PN, the ratio of serum stigmasterol to cholesterol was significantly higher in patients with portal inflammation [134; 98-462] than in those without [41; 30-123; P = 0.045] ( Figure  2 ). An analogous trend was observed for avenasterol [139 (83-306) compared with 65 (53-188), respectively; P = 0.065] (Figure 2 ). Ratios of both serum stigmasterol and avenasterol to cholesterol showed a significant positive correlation with the 1 All values are medians; IQRs in parentheses. Patients weaned off PN were compared with controls, and patients receiving PN were compared with controls, *P , 0.05, **P , 0.005, ***P , 0.001. The ratio to cholesterol is expressed as 3100 mg sterol or squalene/mg cholesterol. PN, parenteral nutrition. 2 Patients receiving PN and patients weaned off PN were compared by using the Mann-Whitney U test. 3 Patients weaned off PN, patients receiving PN, and controls were compared by using the Kruskal-Wallis test.
portal inflammation grade ( Table 4) . In contrast, ratios of sitosterol [2427 (1420-15909) compared with 946 (470-14267), respectively; P = 0.104] and campesterol [415 (238-11040) compared with 244 (155-1618), respectively; P = 0.159] to cholesterol were not significantly different in patients with or without portal inflammation and were not related to portal inflammation (Table 4) . In all patients, the ratio of serum cholestanol to cholesterol was correlated with the portal inflammation grade (Table 4, Figure  3) . In a multivariate linear regression model (adjusted R 2 = 0.139, P = 0.039), including the ratio of serum cholestanol to cholesterol, small-bowel length, and duration of PN, serum cholestanol (b = 0.396, P = 0.012) was the strongest independent predictor of the portal inflammation grade.
Cholestasis
During PN, the ratio of serum avenasterol to cholesterol was significantly higher in patients with histologic cholestasis (281; 93-518) than in those without (72; 61-159; P = 0.047) ( Figure  2 ). An analogous trend was observed for the ratio of stigmasterol to cholesterol [139 (84-688) compared with 80 (34-18), respectively; P = 0.061] (Figure 2 ). The cholestasis grade was correlated positively with ratios of both stigmasterol (r = 0.491, P = 0.053) and serum avenasterol (r = 0.501, P = 0.048) to cholesterol and with serum bile acids (r = 0.523, P = 0.003) ( Table 4) . Ratios of serum sitosterol [4298 (1157-7213) compared with 1369 (473-3119), respectively; P = 0.100] and campesterol [843 (171-955) compared with 277 (122-514), respectively; P = 0.336] to cholesterol were not significantly different in patients with and without cholestasis and were not related to the cholestasis grade (Table 4) . In a univariate linear regression model (adjusted R 2 = 0.241, P = 0.041), the ratio of avenasterol to cholesterol (b = 0.516, P = 0.041) was an independent risk factor for the cholestasis grade during PN.
In all patients, the ratio of serum cholestanol to cholesterol was correlated positively (Table 4, Figure 3 ) and ratios of cholestenol and lathosterol to cholesterol were correlated negatively with the cholestasis grade (Table 4 ). Patients with cholestasis had higher ratios of cholestanol to cholesterol than did patients without cholestasis [467 (248-598) compared with 187 (171-220), respectively; P = 0.011]. In a multivariate regression model (adjusted R 2 = 0.428, P , 0.001), including the ratio of serum cholestanol to cholesterol, small-bowel length, duration of PN, and number of septic episodes, the strongest independent predictor of cholestasis was cholestanol (b = 0.689, P , 0.001).
Steatosis
The liver steatosis grade was associated with the duration of PN and remaining small bowel length (Table 4) . After weaning off PN, patients with histologic steatosis displayed significantly higher ratios of serum cholestenol [98 (52-136) compared with 42 (20-63), respectively; P = 0.009] and lathosterol [441 (259-589) compared with 211 (105-326), respectively; P = 0.008] to cholesterol than those of patients without steatosis (Figure 4) , whereas the steatosis grade was correlated positively with ratio of serum lathosterol to cholesterol (Table 4) .
Fibrosis
Liver fibrosis was related to the duration of PN, remaining small-bowel length, and number of septic episodes (Table 4) . During PN, serum plant sterol ratios and concentrations were not significantly different in patients with than without fibrosis (data not shown) and lacked any significant correlations with the Metavir fibrosis stage (P . 0.05 for all; Table 4 ). However, the Metavir fibrosis stage was positively correlated with the ratio of serum cholestanol to cholesterol (Table 4) .
DISCUSSION
Findings of this population-based cross-sectional study showed, first, that serum concentrations of stigmasterol and avenasterol increase proportionally to portal inflammation as well as biochemical and histologic cholestasis during PN in children with IF, which reinforced their role in associated liver injury. Second, after weaning off PN, persistent liver steatosis occurred in conjunction with increased cholesterol synthesis most likely driven by marked bile acid malabsorption. Third, serum cholestanol was a powerful predictor of histologic liver injury in patients with pediatric-onset IF.
The pathophysiology of IFALD has been linked to defects in bile canalicular adenosine triphosphate-binding casette-transporter family proteins, including the bile salt export pump (BSEP, Abcb11) and multidrug resistance 1 and 2 (mdr1 and mdr2) genes FIGURE 1. During parenteral nutrition, serum stigmasterol (r = 0.754, P = 0.001) and avenasterol (r = 0.799, P , 0.001) ratios to cholesterol showed close correlations with serum conjugated bilirubin concentrations in patients with intestinal failure (n = 16). Correlations were tested by using Spearman's rank correlation test.
encoding P-glycoproteins responsible for the export of bile acids and phospholipids from hepatocytes (13, 37, 38) . On the basis of in vitro studies, the plant sterol stigmasterol has been suggested to promote cholestasis through the inhibition of nuclear receptor FXR and its downstream signaling, resulting in reduced hepatocyte expression of wide variety of FXR-dependent genes, including Abcb11/BSEP and conjugated bilirubin transporter Abcc2 (13, 14, 37) . Another plant sterol, sitosterol, has no effect on FXR in vitro (13) . Gene knockout mice that lack the FXR hepatoprotective mechanisms are ultrasensitive to the bile acid-induced liver injury, and the treatment of rats with the FXR agonist protects against cholestasis (39, 40) . In a mouse model of PNassociated liver disease in which PN infusions were combined with intestinal injury, El Kasmi et al (14) showed that stigmasterol specifically promoted cholestasis, liver injury, and liver macrophage activation . These changes were likely to be mediated through the suppression of canalicular bile transporter expression (Abcb11/BSEP, Abcc2/MRP2) via antagonism of the nuclear receptors FXR and LXR and failure of the upregulation of the hepatic sterol exporters (ABCG5/8) (14) . In accordance with experimental data, in the current study, serum stigmasterol and avenasterol, but not sitosterol or campesterol, increased proportionally to biochemical and histologic cholestasis as well as portal inflammation in patients with IF during PN. The accumulation of serum bile acids, high concentrations of serum stigmasterol and avenasterol, and histologic cholestasis were interrelated. The magnitude of increased serum plant sterol concentrations in children was similar to those reported previously in animal models (14, 41) . Although these finding do not prove causality, they strengthen association between plant sterols and PN-associated liver injury and support the avoidance of intravenous lipid solutions with high plant sterol contents.
We have previously shown that portal inflammation and cholestasis are interrelated in IFALD (4) . In addition to promoting cholestasis, stigmasterol may advocate hepatic inflammation by suppressing FXR signaling, which seems to favor an anti-inflammatory response (42) . Notably, portal inflammation and cholestasis were reduced after weaning off PN. Similar to stigmasterol, avenasterol is included in FIGURE 2. Box-plot graphs show serum stigmasterol-and avenasterol-to-cholesterol ratios in patients with (n = 6) and without (n = 10) portal inflammation or with (n = 5) and without (n = 11) cholestasis during parenteral nutrition and in controls (n = 86). The lines, boxes, and whiskers display medians, IQRs, and 95th percentiles, respectively. The Kruskal-Wallis test was used to compare the 3 groups; P , 0.001 for stigmasterol in portal inflammation, P , 0.001 for stigmasterol in cholestasis, P = 0.122 for avenasterol in portal inflammation, and P = 0.003 for avenasterol in cholestasis. P values in figures show Mann-Whitney U test comparisons between groups. most parenteral lipid emulsions (11) , and the chemical structures of stigmasterol and avenasterol closely resemble each other because they differ only by the side-chain double-bond location, which possibly explains their similar behaviors in the current study. Thus, avenasterol may be involved with the pathogenesis of IFALD via similar molecular mechanisms as stigmasterol, thereby outlining the need for additional research.
In our previous studies, hepatic steatosis in patients with IFALD was closely associated with the remaining small intestinal length and increased serum fibroblast growth factor (FGF) 21 concentration (15). After massive and usually distal small intestinal resection, patients with short-bowel syndrome have shown markedly increased cholesterol synthesis secondary to bile acid malabsorption (16) . Here, increased cholesterol synthesis, as assessed by cholesterol precursor sterols, was further increased in patients with persistent liver steatosis after weaning off PN. Collectively, these findings suggest that bile acid malabsorption may promote hepatic steatosis after weaning off PN in patients with IFALD. Theoretically, ongoing bile acid malabsorption because of a loss of active bile acid absorption sites in the distal ileum could increase hepatic fat accumulation through the decreased activation of FXR and G-protein-coupled bile acid receptor by bile acids (22) . The increased serum concentration of FGF21 and its close association with steatosis in our previous study (15) may be explained by a high dietary fat content and relative malnutrition after weaning off PN (43) because the hepatocyte secretion of FGF21 is increased by chylomicron remnants, a high-fat diet, and starvation (44) . In this respect, additional follow-up of IF patients with liver steatosis and studies of FXR downstream signaling including FGF19 are needed.
Cholestanol is a noncholesterol sterol metabolite of cholesterol that reflects cholesterol absorption under physiologic conditions (45) and is a sensitive indicator of cholestasis in primary biliary cirrhosis and biliary atresia (24) (25) (26) (27) . Cholestanol accumulates into serum mainly because of decreased biliary secretion in cholestatic conditions (25) . In our previous study on neonates with IF who were receiving PN, the ratio of serum cholestanol to cholesterol was related to the serum bilirubin concentration, which suggested that serum cholestanol reflects cholestasis also in neonates with IFALD (10) . In this study, ratios of serum cholestanol to cholesterol were significantly increased in patients who were receiving PN than in those weaned off PN and controls. Moreover, the ratio of serum cholestanol to cholesterol was associated with serum biochemical markers of liver function and histologic liver injury. Specifically, the ratio of serum cholestanol to cholesterol was a strong predictor of histologic cholestasis and portal inflammation grades in regression analyses. These findings further support cholestanol as a useful marker of liver injury in IFALD during and after weaning off PN, which may be exploited in follow-up purposes.
In conclusion, despite having some limitations, including a limited sample size and cross-sectional study design, this study provides new information on interrelations between serum noncholesterol sterols and liver injury in patients with IFALD. We showed, for the first time to our knowledge, that serum concentrations of plant sterols stigmasterol and avenasterol 1 All values are Spearman's rank correlation coefficients in all patients. Serum noncholesterol sterols are ratios to cholesterol (1003 mg/mg cholesterol). *P , 0.05, **P , 0.01, ***P , 0.005.
2 PN, parenteral nutrition. 3 In patients receiving PN (n = 16).
FIGURE 3. Ratio of serum cholestanol ratio to cholesterol was correlated with the liver cholestasis grade (r = 0.428, P , 0.01) and portal inflammation grade (r = 0.511, P , 0.005) in intestinal failure patients. Correlations were tested by using Spearman's rank correlation test. n = 16 patients. PN, parenteral nutrition. increase during PN paralleling liver inflammation, cholestasis, and the accumulation of bile acids in pediatric onset IF. After weaning off PN, increased cholesterol synthesis is associated with persistent liver steatosis, whereas cholestanol appears to be a useful marker of liver injury in patients with IF. Additional clinical research assessing molecular mechanism responsible for the regulation of bile acid and cholesterol metabolism in patients with IFALD is needed.
